Plastic and Reconstructive Surgery

Skip Navigation LinksHome > September 2014 - Volume 134 - Issue 3 > Genome Editing of Mouse Fibroblasts by Homologous Recombinat...
Plastic & Reconstructive Surgery:
doi: 10.1097/PRS.0000000000000427
Experimental: Original Articles

Genome Editing of Mouse Fibroblasts by Homologous Recombination for Sustained Secretion of PDGF-B and Augmentation of Wound Healing

Barker, Jenny C. M.D., Ph.D.; Barker, Adam D. M.D.; Bills, Jessica B.S.; Huang, Jiying B.S.; Wight-Carter, Mary D.V.M.; Delgado, Imelda A.A.; Noble, Debby L. B.S.; Huang, Lily J. Ph.D.; Porteus, Matthew H. M.D., Ph.D.; Davis, Kathryn E. Ph.D.

Supplemental Author Material
Collapse Box


Background: Exogenous cytokines, such as platelet-derived growth factor (PDGF)-B, can augment wound healing, but sustained delivery to maintain therapeutic levels remains a problem. “Genome editing” is a new technology in which precise genome modifications are made within cells using engineered site-specific nucleases. Genome editing avoids many of the complications associated with traditional gene therapy and the use of viral vectors, including random integration, imprecise gene expression, and inadvertent oncogene activation.

Methods: This study demonstrates site-specific nuclease-mediated integration of a PDGF-B transgene into a predefined locus within the genome of primary mouse fibroblasts. Engineered fibroblasts were applied to splinted mouse wounds and evaluated after 14 days and 5 months for the retention of engineered fibroblasts, wound healing morphology, angiogenesis, and systemic PDGF-B expression.

Results: The application of engineered PDGF-B–expressing fibroblasts enhanced wound healing compared with controls. Low-level, constitutive expression of PDGF-B was achieved without detectable levels of systemic PDGF-B. The mechanism of improved wound healing is, at least in part, the result of increased wound vascularization, as the wounds treated with PDGF-B fibroblasts had a blood vessel density 2.5 times greater than controls. After 5 months, the engineered fibroblasts persisted in the wound bed. No adverse effects were detected from the application of these fibroblasts after 5 months as assessed by hematoxylin and eosin staining of wounds and by mouse necropsy.

Conclusions: These data support that site-specific genome editing allows for sustained cell-based cytokine delivery. Furthermore, sustained release of PDGF-B increases the speed and quality of wound healing after a single application.

©2014American Society of Plastic Surgeons


Article Tools


Article Level Metrics

The Clinical Masters of PRS – Breast eBooks

4 Essential eBooks for Plastic Surgeons